Split-belt Treadmill Training to Rehabilitate Freezing of Gait and Balance in Parkinson's Disease
1 other identifier
interventional
28
1 country
1
Brief Summary
Parkinson's disease (PD) related gait and balance disorders are challenging to treat because they cannot be optimized with pharmacological intervention alone. This treatment gap is important to address because gait asymmetry and incoordination are associated with increased falls in this population, which can be functionally debilitating and lead to increased morbidity and mortality. Freezing of gait (FOG) has also been associated with reduced quality of life independent of its association with impaired mobility. Gait disorders therefore represent an unmet need in the treatment of PD. A split-belt treadmill (SB-TM) can be used to adjust the speed of each leg separately and individuals can be prompted to 'adapt' to an asymmetric gait and 're-adapt' with return to symmetrical gait in a phenomenon known as 'after-effect'.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable parkinson-disease
Started Mar 2020
Longer than P75 for not_applicable parkinson-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 27, 2020
CompletedFirst Submitted
Initial submission to the registry
June 12, 2021
CompletedFirst Posted
Study publicly available on registry
July 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2025
CompletedJuly 17, 2024
July 1, 2024
4.7 years
June 12, 2021
July 16, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Falls
The incidence of falls for 3 months after completing treadmill training. Falls will also be assessed at multiple stages during the 7.5-month study period, to understand the duration of benefit of this intervention. This data will be obtained from the falls calendar that will be provided to subjects upon their recruitment to the study.
3 months after completion of treadmill training
Secondary Outcomes (17)
Gait parameters between intervention and control groups
Obtained at baseline evaluation, after 1.5 months of training, and 3-months post intervention
Gait parameters between intervention and control groups
Obtained at baseline evaluation, after 1.5 months of training, and 3-months post intervention
Gait parameters between intervention and control groups
Obtained at baseline evaluation, after 1.5 months of training, and 3-months post intervention
Gait parameters between intervention and control groups
Obtained at baseline evaluation, after 1.5 months of training, and 3-months post intervention
Gait parameters between intervention and control groups
Obtained at baseline evaluation, after 1.5 months of training, and 3-months post intervention
- +12 more secondary outcomes
Study Arms (2)
Intervention group
EXPERIMENTALThe velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%. While the speed of the treadmill will not change throughout the study, the duration of the training will increase each week. In the first week, the SBTM training will take place for 10 minutes. There will be a 5-minute rest period, and the split-belt conditions will continue for another 10 minutes of training (total training time= 20 minutes).
Control group
ACTIVE COMPARATORThe subject will continue to walk under tied-belt conditions adjusted to the over-ground walking speed. In the first week, the treadmill training will be for 10 minutes. They will get a 5-minute break, similar to the intervention group, and continue for another 10 minutes under tied-belt conditions. The duration of each session will increase by 8 minutes every week. For example, in week 1, the treadmill training will be for a total of 20 minutes; in week 2, for 28 minutes; in week 3, for 36 minutes, and so forth, until it gets to 60 minutes by week 6. The rest period will remain at 5 minutes each session, and will always take place at the halfway mark. All 3 sessions in the week will have the same duration of training. If the subject cannot tolerate the velocity or duration of the session, the protocol will be adjusted to most recently tolerated session (and will be recorded for further interpretation and analysis).
Interventions
18 sessions of SB-TM training, where the velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%.
Eligibility Criteria
You may qualify if:
- Idiopathic PD
- Hoehn \& Yahr Stage 2-3, on levodopa
- FOG, resistant to dopaminergic therapy
- Disease duration: 5-15 years
- Stable clinical response to medications or stimulation parameters (in case of DBS) for at least 3 months
- MMSE \>24/30
- Able to walk on a motor-driven treadmill
You may not qualify if:
- Severe imbalance that limits ambulation (Hoehn \&Yahr score above 3)
- Orthopedic conditions and other systemic disease affecting locomotion
- Cardiac conditions limiting the ability to walk uninterrupted for 1 hour
- Presence of other neurological disorder
- Inability to be fluent in English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Toronto Western Hospital
Toronto, Ontario, M5T 2S8, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- This is a prospective, single-blind, parallel-group randomized control trial to assess the feasibility and safety of SBTM in preventing falls and improving gait and balance, as well as its efficacy compared to TM training. The assessor will be blinded to their randomization. Patients will not be blinded to the intervention, and will be informed about the rationale of the study.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinician Investigator, Staff Neurologist
Study Record Dates
First Submitted
June 12, 2021
First Posted
July 1, 2021
Study Start
March 27, 2020
Primary Completion
December 1, 2024
Study Completion
March 1, 2025
Last Updated
July 17, 2024
Record last verified: 2024-07